Galecto stockholders elect three Class III directors and ratify EY as auditor at 2023 annual meeting

Damora Therapeutics, Inc.

Elected Jayson Dallas, Amit Munshi, and Hans Schambye as Class III directors with 9.9M, 10.5M, and 10.5M votes for, respectively.
Ratified EY Godkendt Revisionspartnerselskab as independent auditor for FY 2023 with 16.0M votes for, 52,661 against.
Broker non-votes of 5.5M on director election; no broker non-votes on auditor ratification.
Total shares present or represented: 16.1M out of 25.7M entitled to vote.

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Damora Therapeutics, Inc. shareholders approved Election of Class III Directors at the 2023-06-14 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

(a) Election of Class III Directors. Director Nominee Votes For Votes Withheld Jayson Dallas, M.D. 9,917,146 696,399 Amit Munshi 10,526,701 86,844 Hans Schambye, M.D., Ph.D. 10,508,799 104,746 There were 5,508,817 broker non-votes regarding the election of directors.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Damora Therapeutics, Inc. shareholders approved Ratification of the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-14 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-14

Exact text from the filing

(b) Ratification of the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. Stockholders ratified the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The results of the voting included 16,042,725 votes for, 52,661 votes against and 26,976 votes abstained. There were no broker non-votes regarding this proposal.

View on SEC.gov

Browse all shareholder votes →

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-028265

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.